{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-146299","form_type":"8-K","ticker":"ORGO","cik":"0001661181","company_name":"Organogenesis Holdings Inc.","filed_at":"2022-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.691966+00:00","generated_at":"2026-06-25T21:45:31.513029+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Organogenesis Q1 revenue down 4% to $98.1M; net income drops to $0.1M from $9.9M","bullets":["Net revenue $98.1M, down 4% YoY; adjusted net income $1.2M vs $11.2M.","Surgical & Sports Medicine revenue fell 39% to $7.2M due to ReNu/NuCel discontinuation.","PuraPly revenue grew 29% to $53.3M, partially offsetting declines.","Adjusted EBITDA $5.0M, down 69% from $16.0M; cash at $108.5M.","FY2022 guidance: net revenue $485M-$515M, net income $41.2M-$52.7M."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-146299","json":"https://secwatch.observer/filing/0001193125-22-146299.json","markdown":"https://secwatch.observer/filing/0001193125-22-146299.md","text":"https://secwatch.observer/filing/0001193125-22-146299.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1661181/000119312522146299/0001193125-22-146299-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1661181/000119312522146299/d332410d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T21:45:31.513029+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}